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Abstract 
Background: Drug resistance remains a major obstacle to malaria treatment and control. It can arise and spread rap-
idly, and vary substantially even at sub-national level. National malaria programmes require cost-effective and timely 
ways of characterizing drug-resistance at multiple sites within their countries.
Methods: An improved multiplexed post-PCR ligase detection reaction—fluorescent microsphere assay (LDR-FMA) 
was used to simultaneously determine the presence of mutations in chloroquine resistance transporter (crt), multid-
rug resistance 1 (mdr1), dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) genes in Plasmodium falci-
parum (n = 727) and Plasmodium vivax (n = 574) isolates collected in 2006 from cross-sectional community popula-
tion surveys in two geographically distinct regions (Madang and East Sepik) of Papua New Guinea (PNG) where strong 
regional differences in in vivo aminoquinoline and antifolate therapeutic efficacy had previously been observed. Data 
were compared to those of a follow-up survey conducted in 2010.
Results: Despite some very low parasite densities, the assay successfully amplified all P. falciparum and P. vivax loci 
in 77 and 69 % of samples, respectively. In 2006, prevalences of pfdhfr (59R-108 N) double mutation/wild type pfdhps 
haplotype, pfcrt SVMNT haplotype (72S-76T double mutation), and 86Y pfmdr1 mutation all exceeded 90 %. For P. 
vivax, 65 % carried at least two pvdhfr mutations, 97 % the 647P pvdhps mutation and 54 % the 976F pvmdr1 mutation. 
Prevalence of mutant haplotypes was higher in Madang than East Sepik for pfcrt SVMNT (97.4 vs 83.3 %, p = 0.001), 
pfdhfr (59R-108 N) (100 vs 90.6 %, p = 0.001), pvdhfr haplotypes (75.8 vs 47.6 %, p = 0.001) and pvmdr1 976F (71.2 vs 
26.2 %, p < 0.001). Data from a subsequent Madang survey in 2010 showed that the prevalence of pfdhps mutations 
increased significantly from <5 % to >30 % (p < 0.001) as did the prevalence of pvdhfr mutant haplotypes (from 75.8 
to 97.4 %, p = 0.012).
Conclusions: This LDR-FMA multiplex platform shows feasibility for low-cost, high-throughput, rapid characteriza-
tion of a broad range of drug-resistance markers in low parasitaemia infections. Significant geographical differences 
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Background
Monitoring the emergence and spread of drug resist-
ance is a key priority for malaria control and elimination 
efforts in the modern era [1]. The recent emergence of 
artemisinin resistance in South-east Asia demonstrates 
that drug resistance can spread rapidly across national 
borders and how its prevalence can vary substantially 
even within individual countries [2]. Effective contain-
ment strategies will require comprehensive, accurate, 
real-time estimates of drug resistance status from multi-
ple sites that can identify the potential for treatment fail-
ure within small geographic regions.
In vivo evaluations of drug susceptibility are expen-
sive and logistically challenging, requiring a substantial 
time-commitment from participants and appropriate 
clinical research infrastructure at each study site. Sam-
ple size constraints and the confounding effects of local 
transmission (risk of re-infection) during follow-up can 
compromise comparisons between different geographic 
locations. In vivo evaluations are, therefore, inappropri-
ate for rapid and comprehensive comparisons of drug 
resistance between distinct sites within a single country 
or small geographic area.
The recent development of well-characterized molec-
ular markers that correlate strongly with in  vivo drug 
resistance has meant that there are now feasible alterna-
tive in  vitro methods of characterizing population drug 
resistance. Resistance to sulfadoxine-pyrimethamine (SP) 
in Plasmodium falciparum is clearly linked to mutations 
in the dihydrofolate reductase (pfdhfr) and dihydrop-
teroate synthase (pfdhps) genes with selection thought 
to occur as a step-wise process leading to highly resist-
ant triple to quintuple mutant parasites [3]. There are 
orthologs of these genes in P. vivax [4–8], and pvdhfr 
mutations at codons 57, 58, 61, 117, 173 correlate with 
SP resistance [9, 10]. P. falciparum 4-aminoquinoline 
resistance correlates with mutations in pfcrt [11] and 
pfmdr1. However, the relationship between 4-aminoqui-
noline resistance and mutations in the P. vivax ortholog 
(pvmdr1) remains controversial [12–14] even though it 
seems that a codon 976 mutation is associated with AQ 
or CQ drug resistance in the Asia–Pacific region [13].
Of the four Plasmodium species present in Papua New 
Guinea (PNG), P. falciparum and P. vivax predominate 
[15, 16]. The prevalence of each species differs according 
to the geography of the country and among age groups 
[17]. This complex epidemiology makes malaria control 
in PNG very challenging. Early malaria control efforts in 
PNG included mass drug administration (MDA) in the 
1950s and 1960s [18, 19]. Employed variably throughout 
the country, some areas received MDA with chloroquine, 
some with pyrimethamine and others no drug treat-
ment at all [20]. Anti-malarial treatment policy for case 
management was chloroquine (CQ) for adults or amo-
diaquine (AQ) for young children until 2000 [21]. How-
ever, P. falciparum CQ resistance had started to emerge 
as early as the 1970s [22] and in vivo resistance rates as 
high as 47  % were documented in Madang Province by 
the early 1980s [20]. Resistance in P. vivax emerged much 
later, with the first well-documented CQ treatment fail-
ure described in 1989 [23, 24] and remained at 4.5 % in 
East Sepik by 2000 [25].
In 2000, PNG treatment policy was changed to incor-
porate SP as first-line therapy in combination with 
AQ or CQ. At around that time, P. falciparum PCR-
corrected failure rates ranged from 18.2 to 28.6  % for 
CQ-SP and 10.3 to 21.5 % for AQ-SP in different regions 
[26]. For P. vivax, estimates of resistance to AQ/CQ-SP 
ranged from 0 to 7 % in the same provinces [26] whilst 
uncorrected treatment failure rates of 49  % (28  days) 
and 87  % (42  days) were documented in Madang and 
Sepik in 2005–2006 [27]. However, in contrast to P. 
falciparum, the absence of validated markers to dis-
tinguish recrudescence from reinfection have meant 
that in  vivo comparisons of P. vivax therapeutic effi-
cacy between sites with different malaria epidemiology 
are confounded by both new infections and hypnozoite 
relapses during follow-up, especially in areas of high 
transmission [28].
Following observations of heterogeneity of in vivo drug 
resistance in Madang and East Sepik provinces of PNG 
[26, 29], the utility of an established ligase detection reac-
tion fluorescence microsphere assay (LDR-FMA) was 
investigated [29]. A novel primer set was multiplexed to 
characterize mutations associated with SP and 4-amino-
quinoline resistance in both P. falciparum and P. vivax 
from cross-sectional population surveys conducted in 
these two provinces. The aim of the study was to demon-
strate the feasibility of this high-throughput technology 
as a practical and cost-effective means of rapidly com-
paring susceptibility to multiple drugs at numerous geo-
graphic sites.
in mutation prevalence correlate with previous genotyping surveys and in vivo trials and may reflect variable drug 
pressure and differences in health-care access in these two PNG populations.
Keywords: Plasmodium vivax, Plasmodium falciparum, Malaria, Drug resistance, Molecular markers,  
Papua New Guinea
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Methods
Study population and blood sample collection
Cross-sectional population-wide surveys were con-
ducted in Maprik, East Sepik Province (2006) and Mugil, 
Madang Province (2006 and 2010). Following informed 
consent from adults or children’s guardians, 200  μL of 
whole blood was collected by fingerprick from partici-
pants of all ages. The study was approved by the Medical 
Research Advisory Committee (#05-20) of PNG and the 
PNG Institute of Medical Research Institutional Review 
Board (#06.01).
DNA extraction and molecular diagnosis of Plasmodium 
species infections
Genomic DNA was extracted from whole blood using the 
QIAamp 96 DNA blood kit (Qiagen, Valencia, CA) or the 
96-well genomic DNA extraction kit (Favorgen, Taiwan) 
according to the manufacturer instructions. The presence 
of P. falciparum and P. vivax infections was determined 
by a post-PCR, ligation detection reaction—fluorescent 
microsphere assay (LDR-FMA: 2006 surveys) [30] and a 
qPCR assay (2010 survey) [31, 32].
Detection of mutations in Plasmodium falciparum dhfr, 
dhps and mdr1 genes
Detection of mutations in pfdhfr, pfdhps, pfmdr1 and 
pfcrt was achieved by LDR-FMA using an adaptation of 
the methods of Carnevale et al. [33] and Wong et al. [34]. 
New primers were designed in order to multiplex the 
PCR and perform nested PCR. Primer sequences are pro-
vided in Additional file 1: Table S1. All PCR-1 reactions 
were performed in a buffer containing 120  nM of each 
primer, 67  mM Tris–HCl (pH  =  8.8), 6.7  mM MgSO4, 
16.6  mM (NH4)2SO4, 10  mM mercaptoethanol, 200  µM 
(each) dATP, dGTP, dCTP, dTTP, and 2.5  U of thermo-
stable DNA polymerase. Nested PCR-2 reactions were 
performed with 3  µL of PCR products from the PCR-1 
reaction using the same conditions except for the primers 
(240 nM each). PCR amplification was performed under 
the following conditions: PCR-1—95  °C for 2  min and 
30 cycles at 95 °C for 30 s, 52 °C for 30 s, 72 °C for 80 s, 
and a final extension at 72 °C for 5 min; PCR-2—95 °C for 
2 min and 40 cycles at 95 °C for 30 s, 59 °C for 30 s, 72 °C 
for 1 min, and a final extension at 72 °C for 5 min. Ampli-
fication specificity was evaluated following electropho-
resis on 2 % agarose gel. In order to integrate detection 
of mutations in pfmdr1, new LDR primers were designed 
(sequences provided in Additional file 2: Table S2). LDR-
FMA was performed with 1 μL of PCR-2 product with 
cycling conditions and fluorescence signal interpretation 
as described previously [29, 35].
Because a high background signal for the wild type 
pfmdr 86 allele raised concerns regarding the LDR 
primer’s specificity in polyclonal infections, a PCR RFLP 
protocol was used to confirm LDR-FMA genotyping 
results. PCRs were performed using the same primer sets 
as the LDR-FMA. RFLP was achieved by mixing 5  μL 
of PCR products with 15 μL of a mix containing 1 U of 
ApoI restriction enzyme (New England Biolabs, USA), 
1X NE buffer and 1X BSA. The digestion took place at 
50 °C for 2 h. Digested products were visualized on 2 % 
agarose gel.
Detection of mutations in Plasmodium vivax dhfr, dhps 
and mdr1 genes
Detection of mutations in pvdhfr, pvdhps and pvmdr1 
gene was achieved using a LDR-FMA as described previ-
ously [29]. Two LDR allele-specific primers were added 
to the 23 primers already used in the assay in order to 
integrate two pvdhfr alleles newly identified in PNG by 
sequencing (Additional file 2: Table S2). Fluorescence sig-
nals were interpreted as previously described [28, 35].
Statistics
Chi square and Fisher exact tests (Stata 12) were used 
to compare the frequency of P. falciparum and P. vivax 
infections and mutation prevalence between East Sepik 
and Madang populations.
Results
Study population and Plasmodium infections
As previously detailed [36], a total of 2359 samples, 
including 1282 (54.3 %) from Madang and 1077 (45.7 %) 
from East Sepik, were collected in 2006. Of these, 
784 (61.1  %) samples from Madang and 416 (38.9  %) 
from East Sepik had PCR-detected Plasmodium spp 
(p < 0.001). Plasmodium falciparum was present in 487 
(62.1 %) and 240 (57.7 %) (p = 0.14, NS) and P. vivax in 
409 (52.2  %) and 165 (39.7  %) of infections (p  <  0.001) 
from Madang and East Sepik, respectively. A further 88 P. 
falciparum and 89 P. vivax positive samples collected in a 
2010 survey in Madang were also selected for drug resist-
ance genotyping.
Drug resistance genotyping reveals geographic 
heterogeneity of parasite populations
Plasmodium falciparum genotyping
Of 399 randomly-selected 2006 samples, genotyping 
was successfully performed on the four genes (pfdhfr, 
pfdhps, pfcrt and pfmdr1) in 307 (76.9. %). An additional 
28 samples (7.1 %) yielded results for at least one of the 
four genes. Mutations in pfdhfr, pfdhps and pfmdr1 
were detected individually except for codons 436–437 
of pfdhps. Single gene and multigenic haplotypes were 
only determined in participants displaying a monoclo-
nal infection as determined by the maximum number 
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of alleles (n  =  1) detected at pfdhfr, pfdhps, pfcrt and 
pfmdr1. Genotyping results are displayed in Table  1. 
Over 95 % of isolates displayed a double mutation at pfd-
hfr (59R-108N) and a wild type haplotype at pfdhps. A 
small number (7 samples: 4.8 %) had pfdhps mutations in 
addition to pfdhfr mutations, and thus carried triple or 
quadruple mutant pfdhfr/pfdhps haplotypes.
Most isolates (>90  %) displayed the pfcrt SVMNT 
haplotype (i.e. a double 72S-76T mutations) and a 
pfmdr1 single mutation (86Y). Only one East Sepik 
sample carried the triple mutation (74I-75E-76T) at pfcrt 
(CVIET haplotype). Despite the high overall frequency 
of pfcrt SVMNT and pfdhfr double mutant haplotypes, 
their prevalence was significantly higher in Madang than 
in East Sepik (Table  1: p  =  0.001). These results were 
confirmed when looking at the prevalence of mutations 
in all samples (monoclonal and polyclonal infections). 
Wild-type pfdhfr alleles (codons 59 and 108) were more 
frequent in East Sepik than Madang (p  <  0.001; Addi-
tional file  3: Table S3) as was wild-type CVMNK pfcrt 
Table 1 Pfdhfr, pfdhps, pfcrt and pfmdr1 haplotypes among P. falciparum monoclonal infections
Total 2006 (%) East Sepik 2006 (%) Madang 2006 (%) p value Madang 2010 (%) p value
Monoclonal infections 210 96 114 63
pfdhfr genotype (codons 51-59-108-164)
 Wild type
  N-C-S-I 5 (2.4) 5 (5.2) 0 0.001 0 NS
 Single mutant
  N-C-N-I 3 (1.4) 3 (3.1) 0 0
  N-R-S-I 0 0 0 1 (1.6)
 Double mutant
  I-C-N-I 1 (0.5) 1 (1.0) 0 0
  N-R-N-I 201 (95.7) 87 (90.6) 114 (100) 62 (98.4)
pfdhps genotype (codons 436/437-540-581-613)
 Wild type:
  SA-K-A-A 200 (95.2) 89 (92.7) 110 (96.5) NS 43 (68.3) <0.001
 Single mutant:
  SG-K-A-A 7 (3.3) 3 (3.1) 4 (3.5) 10 (15.9)
 Double mutant
  SG-E-A-A 2 (1.0) 2 (2.1) 0 10 (15.9)
  SG-K-G-A 1 (0.5) 1 (1.0) 0 0
pfcrt genotype (codons 72/73/74/75/76)
 Wild type
  CVMNK 18 (8.6) 15 (15.6) 3 (2.7) 0.001 1 (1.2) NS
 Double mutant
  SVMNT 191 (91.0) 80 (83.3) 111 (97.4) 62 (98.4)
 Triple mutant
  CVIET 1 (0.5) 1 (1.0) 0 0
pfmdr1 genotype (codons 86-184-1034-1042-1246)
 Wild type
  N-Y-S-N-D 10 (4.8) 6 (6.3) 4 (3.5) NS 0 NS
 Single mutant
  Y-Y-S-N-D 196 (93.3) 88 (91.7) 108 (94.7) 62 (98.4)
 Double mutant
  N-F-S-D-D 2 (1.0) 0 2 (1.8) 0
  Y-Y-S-D-D 1 (0.5) 1 (1.0) 0 0
 Triple mutant
  Y-F-S-D-D 0 0 0 1 (1.2)
 Quintuple mutant
  Y-F-C-D-Y 1 (0.5) 1 (1.0) 0 0
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haplotype (p  <  0.001). However pfmdr1 mutations at 
codons 184 and 1042 were more often observed in East 
Sepik (p  =  0.005 and p  =  0.03). Both resistant CVIET 
and SVMNT alleles were found in East Sepik.
Plasmodium vivax genotyping
Genotyping was successfully performed on the three 
genes (pvdhfr, pvdhps and pvmdr1) in 398 (69.3 %) of 574 
P. vivax LDR-FMA samples and at least one of the three 
genes in 483 (84.1 %). As described previously [29], muta-
tions in pvdhfr, pvdhps and pvmdr1 were detected either 
individually (pvdhfr codons 117, 173; pvdhps codons 
553, 647; pvmdr1 codon 976), or as a haplotype (pvdhfr 
codons 57-58-61; pvdhps codons 382–383). For this rea-
son, while it was possible to affirm the presence of triple 
mutant isolates at pvdhfr codons 57-58-61, it was only 
possible to confirm the presence of quadruple mutant 
haplotypes (triple mutant at codons 57-58-61 plus 
mutant at codon 117) in participants with monoclonal 
infections. Genotyping results are displayed in Table 2.
Only 38 of 108 monoclonal isolates (35.2 %) displayed 
a wild type haplotype at pvdhfr with 26 (24.1  %) and 
41 (38.0  %) displaying double and quadruple mutant 
haplotypes, respectively. The vast majority of the iso-
lates (97.2  %) carried the 647P mutation in pvdhps and 
58 (53.7  %) the 976F mutation in pvmdr1. The pvmdr1 
976 mutation itself was highly significantly associated 
with the pvdfhr quadruple mutant haplotype (OR = 5.6; 
CI95  =  [2.3;13.6], p  <  0.001). The prevalence of mutant 
pvdhfr haplotypes was significantly higher in Madang 
than East Sepik (75.8 vs 47.6 %, p = 0.001), with preva-
lence of the quadruple mutant haplotype reaching 51.5 % 
in Madang vs 16.7  % in East Sepik. Similarly, pvmdr1 
976F mutation prevalence was higher in Madang than 
East Sepik (71.2 vs 26.2 %, p < 0.001).
These results were confirmed when including all infec-
tions (monoclonal and polyclonal) (Additional file  4: 
Table S4). Two additional mutations were observed but 
at low frequency: pvdhfr codon 173 (I →  L; 0.4  %) and 
pvdhps codon 647 (A → S; 0.2 %).
Selection of additional mutant genotypes 
under continuous drug pressure
Genotyping results of P. falciparum and P. vivax iso-
lates collected in 2006 in Madang Province were com-
pared with samples collected at the same site in 2010 
Table 2 Pvdhfr, pvdhps and pvmdr1 haplotypes among P. vivax monoclonal infections
Total 2006 (%) East Sepik 2006 (%) Madang 2006 (%) p value Madang 2010 (%) p value
Monoclonal infections 108 42 66 38
pvdhfr genotype (codons 57/58/61-117-173)
 Wild type
  FST-S-I 38 (35.2) 22 (52.4) 16 (24.2) 0.001 1 (2.6) 0.012
 Single mutant
  FST-N-I 1 (0.9) 1 (2.4) 0 0
 Double mutant
  FRT-N-I 4 (3.7) 1 (2.4) 3 (4.5) 1 (2.6)
  LRT-S-I 22 (20.4) 10 (23.8) 12 (18.2) 7 (18.4)
 Triple mutant
  LRT-T-I 2 (1.9) 1 (2.4) 1 (1.5) 3 (7.9)
 Quadruple mutant
  LRM-T-I 41 (38.0) 7 (16.7) 34 (51.5) 26 (68.4)
pvdhps genotype (codons 382/383-553-647)
 Wild type
  SC-A-A 3 (2.8) 0 3 (4.5) NS 4 (10.5) NS
 Single mutant
  SC-A-P 104 (96.3) 42 (100) 62 (93.9) 34 (89.5)
 Double mutant
  SG-A-P 1 (0.9) 0 1 (1.5) 0
pvmdr1 genotype (codon 976)
 Wild type
  Y 50 (46.3) 31 (73.8) 19 (28.8) <0.001 11 (28.9) NS
 Mutant
  F 58 (53.7) 11 (26.2) 47 (71.2) 27 (71.1)
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(Tables  1, 2). As mutant pfdhfr and pfmdr1 genotypes 
had already nearly reached fixation in Madang in 2006, 
no significant change was observed in 2010. The preva-
lence of the pfcrt K76 wild type allele decreased from 
13.6 to 1.2  % (p =  0.002, Additional file  3: Table S3). A 
dramatic increase in the prevalence of pfdhps muta-
tions was observed. In 2010, 15.9 % of isolates carried a 
single mutation (437 G, vs 3.5 % in 2006, p = 0.004) and 
another 15.9  % a double mutation (437G/581G, vs 0  % 
in 2006, p < 0.001). For P. vivax, while the prevalence of 
mutant pvdhps and pvmdr1 haplotypes remained stable 
over time, a significant increase was observed for pvdhfr, 
(97.4 % in 2010 vs 75.8 % in 2006, p = 0.005).
Discussion
The present study shows that the highly multiplexed 
LDR-FMA platform performed well in characteriz-
ing multiple loci related to 4-aminoquinoline and anti-
folate drug resistance in both P. falciparum and P. vivax. 
Through its successful application in low parasite den-
sity infections (from cross-sectional population surveys 
of mostly asymptomatic individuals) and by generat-
ing results highly concordant with existing in  vivo drug 
resistance data (reflecting both spatial and temporal dif-
ferences in population drug resistance profiles), the LDR-
FMA platform can be used for rapid, low-cost application 
at multiple field sites. This makes it an attractive tool 
for national malaria programmes that require compre-
hensive local level characterization of drug resistance 
patterns.
Existing LDR-FMA assays [33, 34] were significantly 
improved by using new PCR primers designed to allow 
visualization of the five amplified fragments of pfmdr1, 
pfcrt, pfdhfr and pfdhps on an agarose gel in a single 
multiplexed assay. Compared with previously published 
LDR-FMA protocols, the new assay requires much less 
total DNA, less technician time and has lower overall 
assay costs. Even though the assay was performed in sam-
ples from mostly asymptomatic individuals who a had 
much lower parasitaemia than previous studies utilizing 
samples from patients with symptomatic infections [34], 
it was only slightly less sensitive for P. vivax and equiva-
lent for P. falciparum [29, 34]. Multiplexing the PCR in 
a nested PCR protocol did not, therefore, compromise 
assay performance significantly. A potential problem in 
the P. falciparum component of the assay related to high 
background signal for the wild type pfmdr 86 allele (that 
raised concerns regarding the LDR primer’s specificity in 
polyclonal infections) was addressed using a PCR RFLP 
protocol. The P. vivax assay was also improved by design-
ing an allele specific primer targeting a new polymor-
phism in the pvdhfr codon 57.
The prevalence of the P. falciparum 4-aminoquinoline 
resistance mutations reported here is very similar to pre-
viously published data including a >80  % prevalence of 
pfmdr1 86Y in 2000–2005 [37–39] and 86–96  % preva-
lence of pfcrt 76T mutation in the early 2000s in East 
Sepik and Madang [33, 37–40]. The pfcrt 76T mutation 
is almost exclusively found as part of the double mutant 
haplotype SVMNT previously described in PNG and 
South America [41, 42]. While this mutation has been 
reaching levels near fixation (96 %) in symptomatic infec-
tions from children from the same geographical area 
(Mugil village, Madang Province) over the last 9  years 
[43], a similar prevalence is observed here in asympto-
matic individuals of all ages.
A recent analysis by Nsanzabana et  al. has suggested 
that strong selection of pfdhfr 59R 108N double mutant 
parasites occurred in East Sepik in the 3 years following 
the introduction of SP in the early 2000s, with a 2.5 times 
increase in double mutant prevalence to 60–70  % over 
this time [44]. This has progressed with levels approach-
ing fixation in the 2006 surveys and other data from the 
same provinces in 2005–2007 [34]. By contrast, the fre-
quency of pfdhps mutations remained very low in 2006 
suggesting some retention of sulfadoxine activity. How-
ever, the emergence of significant rates of single and dou-
ble mutant pfdhps in the 2010 data (combined prevalence 
of 31.8 %) suggests that a loss of SP efficacy may be immi-
nent in Madang Province, thus threatening its potential 
value for intermittent preventive treatment in pregnancy 
and infants.
Despite the very high overall frequency of many muta-
tions in the present study, at least four mutations (pfcrt, 
pfdhfr, pvdhfr haplotypes and the pvmdr1 976F) were sig-
nificantly more prevalent in Madang compared with East 
Sepik, which is in accord with similar observations of dif-
ferences in drug resistance mutations between the two 
areas [37]. One explanation for this phenomenon is that 
the Madang region has more functional health-care infra-
structure and, therefore, its population has better access 
to anti-malarial drugs than the more remote populations 
of the East Sepik [44], resulting in a higher selection pres-
sure. Distribution of drugs beyond their expiration date 
leading to sub optimal dosage could also have contrib-
uted to the selection of drug resistant parasites.
The significant differences in pvmdr1 976F mutation 
prevalence between the two provinces (72 vs 26  % in 
monoclonal infections) and similar differences observed 
for pvdhfr mutant genotypes accord well with the obser-
vations from in vivo studies of SP + CQ or AQ efficacy 
of P. vivax infections between 2003 and 2005 that dem-
onstrated no treatment failure in East Sepik but 29  % 
treatment failures in Madang [26]. Overall, the quadruple 
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pvdhfr genotype was identified in 38.5 % of the P. vivax 
monoclonal infections. This genotype, when found in 
combination with a mutation at pvmdr1 976, has previ-
ously been associated with AQ-SP treatment failure in 
a study conducted in PNG children [9]. Apart from the 
647P mutation that seems to be fixed in the PNG P. vivax 
population, mutations in pvdhps were rarely found.
Plasmodium vivax is characterized by early produc-
tion of gametocytes during its life cycle (prior to the first 
symptoms of malaria) so that transmission can occur 
prior to anti-malarial drug exposure, therefore delay-
ing the selection of drug resistant isolates. However, in 
PNG, the high incidence of mixed P. falciparum/P. vivax 
infections may result in an early exposure of concurrent 
P. vivax infections to anti-malarial drugs at the time of 
treatment of symptomatic malaria caused by P. falcipa-
rum. Additionally, P. vivax polyclonal infections are very 
frequent with up to 75 % of all infected carrying several 
genotypes [45]. This leads to numerous opportunities for 
sexual recombination between parasite clones during the 
mosquito phase of the parasite life cycle and therefore 
production of meiotic recombinant parasites with drug 
resistant genotypes. Despite a lower P. vivax prevalence 
in East Sepik than in Madang, both parasite populations 
have shown similar levels of genetic diversity [36]. There-
fore, as with observations of geographic differences in P. 
falciparum drug resistance mutants, the higher preva-
lence of pvmdr1 and pvdhfr mutants in the Madang P. 
vivax population may reflect greater drug pressure in the 
Madang area.
Like most malaria-endemic countries, PNG has now 
adopted WHO recommended artemisinin combination 
therapy (ACT) as the cornerstone of its anti-malarial 
case-management strategy. This change to ACT has 
already been associated with significant reductions in 
malaria prevalence elsewhere but the emergence and 
spread of artemisinin resistance in South-East Asia [2], 
and observations of variable response to partner drugs 
(such as lumefantrine) [46] suggest the need for ongoing 
surveillance of drug susceptibility to both components. 
Recent identification of an association of particular single 
nucleotide polymorphisms in the kelch-13 gene with arte-
misinin resistant phenotypes [47] may enable incorpora-
tion of markers of artemisinin resistance in combination 
with those evaluated in this study. As demonstrated here, 
the LDR-FMA platform is highly flexible and integration 
of new markers can easily be achieved.
It is also notable that lumefantrine exerts a selective 
pressure on pfmdr1 N86Y in an opposing direction to 
that of AQ and CQ [46, 48, 49]. Therefore, reversion to 
wild-type genotypes following uptake of artemether-
lumefantrine may indicate diminishing parasite 
susceptibility to lumefantrine but may also raise the pros-
pect of resurrecting AQ or CQ as effective treatments.
Conclusion
Significant geographical differences in mutation preva-
lence in the present study correlate with recent in  vivo 
data obtained from the same regions and may reflect 
variable drug pressure due to differences in health-care 
access in the two PNG populations. The high-throughput 
capacity and relatively low cost of the LDR-FMA assay 
could make it a valuable tool for rapidly characterizing 
in a central laboratory the status of resistance to a range 
of anti-malarial drugs from sites that may not neces-
sarily have the infrastructure required for conducting 
in vivo evaluations of drug efficacy. This can be achieved 
by National Malaria Control Programmes and partner 
organizations using isolates obtained through cross-sec-
tional population sampling.
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